Aehealth's immunofluorescence Analyzer (Lamuno series) product participated in the National Glycohemoglobin Standardization Program (NGSP) and successfully passed the certification. which verifies the reliable performance of Lamuno equipment in quantitative detection of glycated hemoglobin and its trustworthy consistency between different laboratories. This shows that Aehealht's glycated hemoglobin analysis and testing platform has reached the level of internationalization, standardization and standardization, and is another milestone in its own quality improvement process.
NGSP is the "National Glycated Hemoglobin Standardization Program" launched by the United States in 1996. This standard is consistent with the results of the American Diabetes Control and Complications Trial (DCCT) and the UK Diabetes Control and Complications Study (UKPDS). It aims to achieve the standardization of glycated hemoglobin testing, ensure the consistency of glycated hemoglobin test results, and make the test results of various clinical laboratories more comparable. It is one of the highest standards for glycated hemoglobin testing in the world and has been recognized by the American Diabetes Association and the FDA.
The principle of immunofluorescence is based on antigen-antibody binding using fluorescent detection. Various antigens such as proteins, glycans, and small biological and non-biological molecules are detected and visualized within cells or tissues using fluorophores.
Lamuno series products have been widely distributed in more than 100 countries and regions and have been well received by many users. Lamuno series products have been widely distributed in more than 100 countries and regions, and have been well received by many users. The Lamuno system is easy to operate and carry, has more than 80 items, a wide range of applications, and can detect multiple items at the same time. It can be used in laboratories, emergency rooms, intensive care units, cardiology departments, etc.